latest update:
[TrialBase DB]

trial summary · NCT07592000

Breakthrough - T1DM and Chronic Kidney Disease

Multicenter, Phase 1/2 Pilot Study of Safety and Efficacy Assessment of Tegoprubart and Calcineurin Inhibitors- Free Immunosuppression Therapy for Pancreatic Islet Transplantation in Patients With T1DM and Chronic Kidney Disease

Trial record from the TrialBase DB dataset, status RECRUITING, condition Diabete Type 1, sponsored by University of Chicago. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07592000phase PHASE1/PHASE2enrollment 10start 2027-04-29

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

Single arm- subject treated with Tegoprubart and everolimus. The purpose of this research is to gather information on the safety and effectiveness of investigational regimen containing 2 experimental components: * An investigational drug called Tegoprubart and * Human pancreatic islet cells Both Tegoprubart and human pancreatic islet cells are considered investigational because they are not approved for use in the United States by the Food and Drug Administration (FDA). Participation in this research will last about 5 years. Assess safety, tolerability, and efficacy of transplanted islet cells and immunomodulation with Tegoprubart in combination with anti-thymocyte globulin (ATG), etanercept and with everolimus in adults with brittle T1D and chronic kidney disease (stage 2-3a).

Source record: https://clinicaltrials.gov/study/NCT07592000

Facts

registry idNCT07592000
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1/PHASE2
study typeINTERVENTIONAL
lead conditionDiabete Type 1
sponsorUniversity of Chicago
sponsor classOTHER
enrollment10
start date2027-04-29
primary completion2030-01-31
completion2030-01-31
results postednot reported

Conditions

  • Diabete Type 1
  • Chronic Kidney Disease

Interventions

  • Tegoprubart
  • Islet Cell Transplant

Countries

  • United States

Intervention types: BIOLOGICAL, DRUG

Work with this record